摘要
目的:研究奥沙利铂(Oxaliplatin,Ox)调控PI3K/Akt信号通路抑制脑胶质瘤细胞株U87生长的作用。方法:培养U87脑胶质瘤细胞,分别利用0、20、40、80μg/ml的奥沙利铂处理U87细胞24、36、48、72 h,利用MTT检测各处理组细胞增殖情况;利用流式细胞仪检测40μg/ml的奥沙利铂处理48 h对U87细胞周期及细胞凋亡的影响;Western blot检测40μg/ml的奥沙利铂处理48 h对U87细胞凋亡相关蛋白及PI3K/Akt信号通路蛋白表达的影响。结果:奥沙利铂处理抑制U87细胞增殖,与0μmol/L处理相比,差异显著(P<0.01),40μg/ml的奥沙利铂处理48 h差异最显著。40μg/ml的奥沙利铂处理48 h后,U87细胞周期被阻滞在S期,U87细胞凋亡显著增加(P<0.01),抑凋亡因子Bcl-2蛋白表达明显下降,促凋亡因子Bax、Cleaved-caspase3蛋白表达明显升高(P<0.01),PI3K及p-Akt的表达量明显降低(P<0.01),Akt表达量无明显差异(P>0.05)。结论:奥沙利铂可能通过抑制PI3K/Akt信号通路抑制U87细胞增殖,阻滞细胞周期,促进细胞凋亡。
Objective： To investigate the effect of oxaliplatin inhibit the growth in glioma U87 cells by regulating PI3K/Akt signal pathway. Methods： The glioma U87 cells were cultivated in vitro,using 0,20,40,80 μg / ml oxaliplatin treated U87 cells 24,36,48,72 h respectively,MTT was used to detect cell proliferation. Using 40 μg / ml oxaliplatin treated U87 cells 48 h,flow cytometry was used to detect cell cycle and apoptosis. Cells apoptosis protein and PI3 K / Akt pathway protein expression after 40 μg / ml oxaliplatin treated U87 cells 48 h was detected by Western blot. Results： MTT assay showed that compared with the 0 μg / ml treatment,oxaliplatin treatment could significantly inhibited U87 cell survival（ P〈0. 01）,40 μg / ml oxaliplatin treatment 48 h,the survival inhibitory was the most obvious. U87 cell cycle was arrested in S phase after 40 μg / ml oxaliplatin treatment 48 h. After 40 μg / ml oxaliplatin treatment 48 h,compared with the 0 μg / ml treatment,U87 cell apoptosis rate significantly increased（ P〈0. 01）. Western blot showed that after 40μg /ml oxaliplatin treatment,anti-apoptotic factor Bcl-2 expression had significant decreased,pro-apoptotic factors Bax,Cleavedcaspase3 protein expression had significantly increased（ P〈0. 01）. PI3 K,p-Akt expression was significantly decreased（ P〈0. 01）,and Akt expression had no significant change in Akt pathway（ P〉0. 05）. Conclusion： Oxaliplatin may suppress U87 cell proliferation,arrest cell cycle,and promote apoptosis by inhibit PI3 K / Akt signaling pathway.
作者
段友强
刘义锋
李巍
DUAN You-Qiang LIU Yi-Feng LI Wei(Department of Neurosurgery, Zhengzhou Central Hospital Affiliated to Zheng- zhou University, Zhengzhou 450007, Chin)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2017年第3期328-332,共5页
Chinese Journal of Immunology
基金
国家自然科学基金项目(No.81401097)
